Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
This star-forming galaxy is blowing out powerful winds topping 2 million mph - 2Instructions to Guarantee Kids Foster Solid Dental Propensities
- 3Get away from the Tedious Drudgery: Go into Business Today!
- 4Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- 5Somalia set for 'historic' first offshore oil drilling
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- Tech Devices 2023: The Most blazing Arrivals of the Year
- 5 Advancement Developments in Biotechnology
- Mossad unveils network of Hamas terror infrastructure across Europe
- UN experts urge investigation into Israel’s killing of Lebanese journalists
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026
- Vote In favor of Your #1 Method for diminishing Pressure
